199 related articles for article (PubMed ID: 27153824)
1. Linking the Price of Cancer Drug Treatments to Their Clinical Value.
Gozzo L; Navarria A; Drago V; Longo L; Mansueto S; Pignataro G; Cicchetti A; Salomone S; Drago F
Clin Drug Investig; 2016 Jul; 36(7):579-89. PubMed ID: 27153824
[TBL] [Abstract][Full Text] [Related]
2. An expanded portfolio of survival metrics for assessing anticancer agents.
Karweit J; Kotapati S; Wagner S; Shaw JW; Wolfe SW; Abernethy AP
Am J Manag Care; 2017 Jan; 23(1):54-61. PubMed ID: 28141932
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
[TBL] [Abstract][Full Text] [Related]
4. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
6. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
7. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Hill A; Redd C; Gotham D; Erbacher I; Meldrum J; Harada R
BMJ Open; 2017 Jan; 7(1):e011965. PubMed ID: 28110283
[TBL] [Abstract][Full Text] [Related]
8. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
9. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
Franken MD; van Rooijen EM; May AM; Koffijberg H; van Tinteren H; Mol L; Ten Tije AJ; Creemers GJ; van der Velden AMT; Tanis BC; Uyl-de Groot CA; Punt CJA; Koopman M; van Oijen MGH
Eur J Cancer; 2017 Apr; 75():204-212. PubMed ID: 28237866
[TBL] [Abstract][Full Text] [Related]
11. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
12. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
Parmar A; Jiao T; Saluja R; Chan KKW
Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
[TBL] [Abstract][Full Text] [Related]
13. The impact of pricing strategy on the costs of oral anti-cancer drugs.
Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
15. Why clinical oncologists should talk about the price of cancer drugs.
Berlinger N
Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
[No Abstract] [Full Text] [Related]
16. Drug Prices and Value of Oncology Drugs in Italy.
Russo P; Marcellusi A; Zanuzzi M; Carletto A; Fratto ME; Favato G; Staniscia T; Romano F
Value Health; 2021 Sep; 24(9):1273-1278. PubMed ID: 34452706
[TBL] [Abstract][Full Text] [Related]
17. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
Foote J; Secord AA; Liang M; Cohn DE; Jewell E; Havrilesky LJ
J Oncol Pract; 2017 Dec; 13(12):e1030-e1039. PubMed ID: 29016225
[TBL] [Abstract][Full Text] [Related]
18. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
